Summary of Nektar Therapeutics Conference Call Company and Industry - **Company**: Nektar Therapeutics - **Industry**: Biotechnology, specifically focusing on treatments for autoimmune and inflammatory conditions, with a current emphasis on dermatological diseases such as atopic dermatitis and alopecia areata Core Points and Arguments 1. **Therapeutic Strategy**: Nektar's strategy focuses on advancing innovative therapies for serious autoimmune and inflammatory conditions, particularly through immune system rebalancing to achieve immune homeostasis for patients [6][46] 2. **Rezpeg Overview**: Rezpeg is a first-in-class Treg stimulator based on IL-2, validated as a best-in-class approach for treating atopic dermatitis, differentiating itself from other IL-2 agonists [6][7] 3. **Clinical Trial Results**: The Phase IIb trial for Rezpeg in atopic dermatitis showed statistically significant results across primary and secondary endpoints, with a p-value of less than 0.001 for the primary endpoint [7][16] 4. **Efficacy Metrics**: - The trial met its primary endpoint of mean improvement in EASI score at week sixteen for all three arms of Rezpeg versus placebo - Key secondary endpoints such as EZ75, EZ50, and BSA also achieved statistical significance [7][17] - The highest dose of 24 micrograms per kilogram every two weeks achieved significance on the EZ90 endpoint [7][17] 5. **Rapid Onset of Response**: A rapid onset of response was observed, particularly for EZ75 and itch, differentiating Rezpeg from other immune modulation approaches [8][19] 6. **Safety Profile**: The safety profile was consistent with previous results, with less than 1% of patients discontinuing due to injection site reactions (ISRs) and no increased incidence of conjunctivitis or infections compared to placebo [8][26] 7. **Translational Data**: Rezpeg reduced key Th2-related inflammatory markers associated with atopic dermatitis, indicating a meaningful immunological impact [21][22] 8. **Future Studies**: Nektar is eager to evaluate Rezpeg in alopecia areata, with results expected in Q4 2023, and plans to present 52-week maintenance data in early 2026 [9][49] Additional Important Content 1. **Patient Demographics**: The study enrolled 393 biologic-naive patients with moderate to severe atopic dermatitis, predominantly from Europe, North America, and Australia [10][14] 2. **Placebo Response Rate**: The low placebo response rate of 31% was noted as a significant achievement, indicating effective management of placebo effects [17][66] 3. **Dosing Strategy**: The company is considering a single dose level for Phase III based on the successful dose range observed in Phase IIb [62][63] 4. **Potential for Other Indications**: Nektar sees potential for Rezpeg in other dermatological conditions such as lupus and vitiligo, as well as in type 1 diabetes [51][52] 5. **ISR Mitigation Strategies**: Nektar is planning to implement strategies to mitigate ISRs, including the use of an auto-injector for self-administration [28][81] 6. **Expert Opinions**: Key opinion leaders expressed confidence in the study design and results, highlighting the potential for sustained and deepening responses in future studies [44][70] This summary encapsulates the key points discussed during the conference call, focusing on the efficacy, safety, and future potential of Rezpeg in treating atopic dermatitis and other conditions.

Phase 2b REZOLVE-AD Topline Results from 16-Week Induction Rezpegaldesleukin in Patients with Moderate-to- Severe Atopic Dermatitis June 24, 2025 1 Forward-Looking Statements Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Nektar Therapeutics (the "Company" or "Nektar")'s plans, progress, and timing ...

Core Insights - Nektar Therapeutics announced statistically significant results from the Phase 2b REZOLVE-AD study of rezpegaldesleukin for atopic dermatitis, achieving primary and key secondary endpoints at week 16 [1][3][4] - The study demonstrated a rapid onset of Eczema Area and Severity Index (EASI) reduction and itch improvement, indicating the potential of rezpegaldesleukin as a first-in-class immune-modulator [1][7] - The safety profile of rezpegaldesleukin was consistent with previous reports, with the most common adverse events being mild to moderate injection site reactions [12][13] Study Design and Results - The global Phase 2b study involved 393 patients with moderate-to-severe atopic dermatitis, randomized to receive different dosing regimens of rezpegaldesleukin or placebo [2][18] - At week 16, the high dose (24 µg/kg every two weeks) showed a mean improvement in EASI score of 61%, while the middle and low doses showed improvements of 58% and 53%, respectively, all statistically significant compared to placebo [8][12] - Key secondary endpoints, including EASI-75 and EASI-90, also achieved statistical significance, with 42% and 25% of patients in the high dose group achieving these reductions, respectively [4][6] Efficacy and Biomarkers - The study revealed a robust dose-dependent reduction in inflammatory biomarkers associated with atopic dermatitis, including IL-19 and TARC/CCL17, with a notable increase in total regulatory T cells (Tregs) in the high dose group [9][10] - The results suggest that rezpegaldesleukin may offer a new therapeutic approach for treating dermatological diseases, with ongoing studies expected to provide further insights [9][10] Future Developments - Nektar plans to present the 16-week induction results at a medical conference later in 2025 and anticipates top-line data for alopecia areata in Q4 2025 [11][21] - The FDA granted Fast Track designation for rezpegaldesleukin for treating moderate-to-severe atopic dermatitis, indicating the potential for expedited development [21][22]

Company Overview - Nektar Therapeutics is a clinical-stage biotechnology company focused on developing novel immunology therapies for autoimmune and chronic inflammatory diseases [3] - The company's lead product candidate, rezpegaldesleukin (REZPEG or NKTR-358), is a first-in-class regulatory T cell stimulator currently being evaluated in two Phase 2b clinical trials, one for atopic dermatitis and another for alopecia areata [3] - Nektar's pipeline includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422 [3] - The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist aimed at enhancing the immune system's ability to combat cancer, in several ongoing clinical trials [3] Upcoming Events - Nektar Therapeutics will host an investor call and live webcast on June 24, 2025, to review top-line data from the 16-week induction period of the Phase 2b REZOLVE-AD clinical trial for rezpegaldesleukin [1] - The data will be released in a morning press release and presented during the webcast, with access details available on the Nektar website [2]

Group 1 - Nektar Therapeutics (NASDAQ: NKTR) is preparing for a significant catalyst in June 2025, with the upcoming release of data from its phase 2b REZOLVE-AD study [2] - The REZOLVE-AD study is evaluating the use of REZPEG (NKTR-358) [2] Group 2 - The Biotech Analysis Central service offers in-depth analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [1][2]

Core Insights - Ambrosia-Nektar Inc. is a new player in the international organic food market, launching a premium product line featuring high-end organic food sourced from Greece [1][7] - The brand emphasizes single-ingredient food made with organic, non-GMO ingredients from small artisan producers, focusing on quality and authenticity [4][8] - The company aims to meet the growing consumer demand for transparency and premium quality in food products [6] Product Categories - The product line includes three core categories: - Herbs & Infusions: Featuring wild oregano, mountain tea, and herbal blends known for flavor and wellness benefits [7] - Liquid Sustenance: Offering organic extra virgin olive oil, wild forest honey, and pomegranate juice, showcasing the biodiversity of Greece [7] - Gift Sets: Elegant assortments designed for gifting, combining traditional Greek staples with luxurious packaging [7] Company Philosophy - Ambrosia-Nektar's mission is to reconnect consumers with food in its purest form, supporting local agricultural traditions while ensuring product purity and safety through lab testing [5][8] - The brand's commitment to transparency and traceability from source to shelf is a key aspect of its operations [4][6]

Financial Data and Key Metrics Changes - The company ended the fourth quarter with approximately $221 million in cash, providing a runway until the fourth quarter of 2026 with existing operations [40] Business Line Data and Key Metrics Changes - Respag, a drug developed by the company, demonstrated dose-dependent efficacy in a Phase 1b study for atopic dermatitis, with a significant improvement in the eczema area and severity index (EASI) score after correcting previous data errors [4][6] - The Phase 2b study for atopic dermatitis is set to enroll 400 patients, extending the dosing period to 16 weeks and including a maintenance arm for ongoing treatment [14][15] Market Data and Key Metrics Changes - The company is entering the alopecia market, where currently only JAK inhibitors are approved, positioning Respag as a potential first biologic treatment in this space [35] Company Strategy and Development Direction - The company aims to leverage its unique mechanism of action with Respag, which stimulates regulatory T cells, to differentiate itself from existing treatments in the atopic dermatitis and alopecia markets [10][32] - The partnership with TrialNet focuses on the role of Tregs in type 1 diabetes, indicating a strategic move into autoimmune disease prevention [38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the Phase 2b study for atopic dermatitis, citing the robust design and previous positive results as indicators of potential success [16][19] - The company anticipates presenting top-line results for both the atopic dermatitis and alopecia studies in June and December respectively, highlighting a proactive approach to clinical development [34] Other Important Information - The company has transitioned Respag to a wholly owned asset after terminating its collaboration with Eli Lilly, allowing for independent development in multiple clinical trials [2] Q&A Session Summary Question: Can you provide an overview of the Respag history? - The company developed Respag and initially partnered with Eli Lilly in 2017, completing nine clinical studies before terminating the collaboration in April 2023 [2] Question: What are the expectations for the Phase 2b study? - The company aims to replicate the significant efficacy observed in the Phase 1b study, targeting a similar effect size with a larger patient population [19] Question: How is the company addressing the placebo effect in clinical trials? - The company has minimized the US footprint in trial enrollment and ensured that the majority of sites are led by board-certified dermatologists to maintain consistency in disease rating [24][26]

SAN FRANCISCO, May 13, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held at the Nasdaq Headquarters in New York City on May 20, 2025: H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 20, 2025 – webcast to be available at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time – link hereThe fireside chat will be accessible via the webcast l ...

Nektar Therapeutics (NKTR) incurred a first-quarter 2025 adjusted loss of 22 cents per share, wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, the company had reported a loss of 18 cents per share.Total revenues in the first quarter decreased 51.4% year over year to $10.5 million. The reported figure also missed the Zacks Consensus Estimate of $18 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The year-over-year revenue decrease was d ...

Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.13 per share when it actually produced a loss of $0.15, delivering a surprise of -15.38%.Over the last four quarters, ...